Eli Lilly and Company (NYSE:LLY) Stock Jumps 2.5% – Should You Buy?

Shares of Eli Lilly and Company (NYSE:LLY) rose 2.5% during mid-day trading on Wednesday. The company traded as high as $1,206.63 and last traded at $1,186.95. Approximately 2,294,125 shares traded hands during trading, a decline of 23% from the average daily volume of 2,971,630 shares. The stock had previously closed at $1,157.49.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Next-generation obesity treatments could extend Lilly’s growth runway. Analysts highlighted retatrutide, Lilly’s triple-hormone candidate, which has produced greater average weight loss than Zepbound in trials and could be filed with the FDA in 2027. Potential applications in fatty liver disease, sleep apnea and other conditions could expand the addressable market. Lilly retatrutide article
• Positive Sentiment: Foundayo data strengthened the oral GLP-1 opportunity. Lilly presented analysis showing its oral GLP-1 candidate delivered greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes. A successful oral product could improve convenience, broaden adoption and support future revenue growth, although the analysis has limitations and competition remains intense. Foundayo data article
• Positive Sentiment: Investors are seeing growth beyond weight loss. Commentary pointed to emerging contributions from Lilly’s oncology, immunology and neuroscience portfolios, as well as progress in early-stage programs including basal insulin and elt​​rekibart. The breadth of the pipeline supports the view that Lilly is more than a single-product obesity story. Lilly pipeline growth article
• Neutral Sentiment: Momentum is building ahead of third-quarter earnings. Recent commentary cited strong sales growth, favorable expectations and technical momentum. Lilly’s latest reported quarter substantially exceeded analyst estimates, but investors will look for continued execution and guidance support at the next earnings release. Lilly earnings momentum article
• Negative Sentiment: Valuation leaves limited room for disappointment. With LLY valued near 40 times trailing earnings and carrying a market capitalization above $1 trillion, analysts warned that much of the GLP-1 growth outlook is already reflected in the stock. Pricing pressure, reimbursement challenges and the long regulatory path for new drugs could create volatility. Lilly valuation article
• Negative Sentiment: New WHO childhood-obesity guidelines may add pressure. The guidelines discourage weight-loss medication use as a standalone solution for children and adolescents, emphasizing broader interventions. That could constrain or delay one potential expansion area for Lilly and Novo Nordisk, although the direct near-term revenue impact is uncertain. WHO childhood obesity guidelines article

Analysts Set New Price Targets

A number of analysts have weighed in on LLY shares. HSBC increased their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. Citigroup upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Bank of America raised their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,312.36.

Eli Lilly and Company Trading Up 2.5%

The firm has a market capitalization of $1.12 trillion, a PE ratio of 39.83, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company’s 50-day simple moving average is $1,173.98 and its 200 day simple moving average is $1,092.69.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 36.66 EPS for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Coastal Bridge Advisors LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth $2,959,000. Mosaic Family Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 70.6% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after buying an additional 1,430 shares during the last quarter. Moran Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 85.6% during the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after acquiring an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC boosted its position in shares of Eli Lilly and Company by 17.5% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after acquiring an additional 1,521 shares in the last quarter. Finally, Amundi increased its holdings in shares of Eli Lilly and Company by 9.9% in the 1st quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after acquiring an additional 454,549 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.